306:
29:
577:(GHRH) in humans, and produces synergistic effects on GH release in combination with GHRH, resulting in "massive" increases in plasma GH levels even with only low doses of examorelin. Pre-administration of GH blunts the GH-releasing effect of examorelin, while, in contrast, fully abolishing the effect of GHRH. Pre-treatment with IGF-1 also blunts the GH-elevating effect of examorelin.
421:
InChI=1S/C47H58N12O6/c1-27-34(33-15-7-9-17-37(33)54-27)23-41(58-44(62)35(49)22-31-25-51-26-53-31)45(63)55-28(2)43(61)57-40(21-30-24-52-36-16-8-6-14-32(30)36)47(65)59-39(20-29-12-4-3-5-13-29)46(64)56-38(42(50)60)18-10-11-19-48/h3-9,12-17,24-26,28,35,38-41,52,54H,10-11,18-23,48-49H2,1-2H3,(H2,50,60)(H,51,53)(H,55,63)(H,56,64)(H,57,61)(H,58,62)(H,59,65)/t28-,35-,38-,39+,40-,41+/m0/s1
379:
924:
Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, et al. (1997). "Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH".
650:
Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F (March 1994). "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man".
968:
Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, et al. (October 1996). "Short-term administration of intranasal or oral
Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging".
1353:
Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, et al. (February 1995). "The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects".
1169:
Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, et al. (January 1997). "Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man".
1389:
Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, et al. (April 1995). "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty".
1553:
1047:
Frenkel J, Silbergeld A, Deghenghi R, Laron Z (1995). "Short term effect of intranasal administration of hexarelin--a synthetic growth hormone-releasing peptide. Preliminary communication".
604:
A partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50–75% decrease in efficacy over the course of weeks to months).
2247:
1090:
Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, et al. (January 1995). "Metabolic modulation of the growth hormone-releasing activity of hexarelin in man".
554:(IGFBP-1) levels in humans, with some studies finding no increase and others finding a slight yet statistically significant increase. Examorelin does not affect plasma levels of
98:
1004:
Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A (November 1995). "Intranasal administration of the GHRP hexarelin accelerates growth in short children".
1205:
Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, et al. (January 1995). "Modulation of growth hormone-releasing activity of hexarelin in man".
1546:
695:
Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, et al. (1994). "Growth hormone-releasing activity of hexarelin in humans. A dose-response study".
1562:
551:
393:
1539:
2252:
2200:
1902:
151:(2S)-6-amino-2-amino]-3-(2-methyl-1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
2222:
2237:
1477:
1296:
776:
749:
1982:
631:
480:
1240:
Massoud AF, Hindmarsh PC, Brook CG (November 1995). "Hexarelin induced growth hormone release is influenced by exogenous growth hormone".
593:, have been found to significantly potentiate the GH-releasing effects of examorelin in humans. In accordance, likely due to increases in
2232:
440:
413:
1937:
574:
143:
1725:
563:
547:
245:
2227:
608:
567:
539:
484:
285:
515:. These GH-releasing peptides have no sequence similarity to ghrelin, but mimic ghrelin by acting as agonists at the
401:
CC1=C(C2=CC=CC=C2N1)C(C(=O)N(C)C(=O)N(CC3=CNC4=CC=CC=C43)C(=O)N(CC5=CC=CC=C5)C(=O)N(CCCCN)C(=O)N)NC(=O)(CC6=CNC=N6)N
615:
578:
1635:
1625:
795:
Moulin A, Ryan J, Martinez J, Fehrentz JA (September 2007). "Recent developments in ghrelin receptor ligands".
619:
214:
488:
1583:
72:
1615:
582:
472:
456:
83:
1842:
274:
2242:
1740:
205:
1882:
1660:
2185:
2161:
1610:
301:
122:
2007:
1767:
1600:
2156:
1942:
1822:
1605:
843:
Wang Y, Tomlinson B (March 2009). "Tesamorelin, a human growth hormone releasing factor analogue".
559:
496:
468:
160:
91:
2002:
1867:
1314:"The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids"
1892:
1802:
1782:
1715:
1680:
1670:
1640:
1575:
1518:
1265:
1072:
1029:
950:
903:
886:
Carpino PA (2002). "Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists".
868:
820:
720:
2062:
1947:
1887:
1772:
1690:
1685:
1650:
2141:
2136:
2119:
2109:
2067:
1932:
1922:
1877:
1832:
1792:
1787:
1757:
1700:
601:
has also been found to significantly augment the GH-elevating actions of examorelin in humans.
2151:
2012:
1972:
1630:
1510:
1473:
1467:
1448:
1407:
1371:
1335:
1292:
1284:
1257:
1222:
1187:
1148:
1107:
1064:
1021:
986:
942:
860:
812:
772:
766:
745:
739:
712:
668:
2175:
2170:
1852:
1847:
234:
2042:
2037:
2032:
2027:
1857:
1827:
1762:
1502:
1438:
1399:
1363:
1325:
1249:
1214:
1179:
1138:
1099:
1056:
1013:
978:
934:
895:
852:
804:
704:
660:
586:
460:
322:
169:
114:
254:
1127:"Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study"
305:
1312:
Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, et al. (March 1997).
1620:
1572:
1253:
1017:
611:
527:
1183:
938:
2216:
1531:
1103:
1522:
1269:
1033:
954:
907:
872:
824:
724:
194:
2104:
1837:
1655:
1076:
523:
28:
546:
in humans. There are conflicting reports on the ability of examorelin to elevate
2124:
2082:
2077:
2072:
2057:
1962:
1957:
1817:
1777:
1705:
1645:
1506:
1493:
Suckling K (November 2006). "Discontinued drugs in 2005: cardiovascular drugs".
899:
594:
590:
534:(GHRP-2) and GHRP-6, it slightly and dose-dependently stimulates the release of
531:
492:
79:
1143:
1126:
2114:
2099:
2087:
2052:
1952:
1862:
1812:
1807:
1797:
1675:
1403:
1367:
919:
917:
856:
664:
355:
225:
87:
1164:
1162:
1060:
2129:
2094:
535:
1514:
1443:
1426:
1330:
1313:
864:
816:
808:
20:
1452:
1411:
1375:
1339:
1261:
1226:
1191:
1152:
1111:
1068:
1025:
990:
982:
946:
716:
672:
1927:
1665:
543:
2022:
708:
598:
555:
516:
476:
464:
180:
1469:
Growth
Hormone Secretagogues: Basic Findings and Clinical Implications
1218:
2047:
768:
Concise
Dictionary of Pharmacological Agents: Properties and Synonyms
512:
265:
1289:
Bioactive
Peptides: Applications for Improving Nutrition and Health
378:
369:
690:
688:
686:
684:
682:
1535:
290:
1427:"Growth hormone status during long-term hexarelin therapy"
1741:
622:
but did not complete development and was never marketed.
1903:
771:. Springer Science & Business Media. pp. 117–.
522:
Examorelin substantially and dose-dependently increases
1726:
530:(GH) in animals and humans. In addition, similarly to
2186:
1567:
1431:
The
Journal of Clinical Endocrinology and Metabolism
1392:
The
Journal of Clinical Endocrinology and Metabolism
1356:
The
Journal of Clinical Endocrinology and Metabolism
1318:
The
Journal of Clinical Endocrinology and Metabolism
1131:
The
Journal of Clinical Endocrinology and Metabolism
1125:
Massoud AF, Hindmarsh PC, Brook CG (December 1996).
653:
The
Journal of Clinical Endocrinology and Metabolism
2184:
1983:
1981:
1901:
1739:
1582:
1049:
Journal of Pediatric Endocrinology & Metabolism
367:
354:
321:
316:
284:
264:
244:
224:
213:
204:
179:
159:
134:
121:
113:
97:
71:
40:
35:
1636:Placental growth hormone (growth hormone variant)
193:
168:
2248:World Anti-Doping Agency prohibited substances
838:
836:
834:
790:
788:
1547:
8:
738:Ganellin CR, Triggle DJ (21 November 1996).
552:insulin-like growth factor-binding protein 1
481:ghrelin/growth hormone secretagogue receptor
19:
1425:Rahim A, O'Neill PA, Shalet SM (May 1998).
1554:
1540:
1532:
304:
233:
1442:
1329:
1142:
697:European Journal of Clinical Pharmacology
253:
1495:Expert Opinion on Investigational Drugs
845:Expert Opinion on Investigational Drugs
642:
418:
398:
300:
148:
1731:Tooltip Growth hormone-binding protein
1584:
1563:
765:Morton IK, Hall JM (6 December 2012).
573:Examorelin releases more GH than does
18:
888:Expert Opinion on Therapeutic Patents
273:
7:
741:Dictionary of Pharmacological Agents
632:List of growth hormone secretagogues
184:
1254:10.1111/j.1365-2265.1995.tb02927.x
1018:10.1111/j.1365-2265.1995.tb02929.x
14:
2253:Experimental cardiovascular drugs
971:European Journal of Endocrinology
1283:Owusu-Apenten R (23 June 2010).
575:growth hormone-releasing hormone
339:
333:
27:
426:Key:RVWNMGKSNGWLOL-GIIHNPQRSA-N
2223:Drugs not assigned an ATC code
1676:Somatrogon (MOD-4023; hGH-CTP)
345:
327:
1:
1184:10.1016/s0026-0495(97)90173-6
939:10.1016/s0196-9781(97)00016-8
2238:Growth hormone secretagogues
1291:. CRC Press. pp. 292–.
1104:10.1016/0026-0495(95)90300-3
744:. CRC Press. pp. 617–.
564:follicle-stimulating hormone
548:insulin-like growth factor 1
443:) (developmental code names
1713:Antisense oligonucleotides:
1507:10.1517/13543784.15.11.1299
1472:. Elsevier. pp. 178–.
900:10.1517/13543776.12.11.1599
568:thyroid-stimulating hormone
540:adrenocorticotropic hormone
485:growth hormone secretagogue
2269:
1144:10.1210/jcem.81.12.8954038
317:Chemical and physical data
2233:Ghrelin receptor agonists
1404:10.1210/jcem.80.4.7714074
1368:10.1210/jcem.80.2.7852535
857:10.1517/13543780802707658
665:10.1210/jcem.78.3.8126144
616:growth hormone deficiency
409:
389:
139:
26:
1626:Human placental lactogen
1061:10.1515/jpem.1995.8.1.43
620:congestive heart failure
511:which was derived from
489:Mediolanum Farmaceutici
487:which was developed by
475:, and highly selective
2018:Examorelin (hexarelin)
1444:10.1210/jcem.83.5.4812
1331:10.1210/jcem.82.3.3795
1285:"Anabolic Dysfunction"
1242:Clinical Endocrinology
1006:Clinical Endocrinology
809:10.1002/cmdc.200700015
583:testosterone enanthate
503:-2-methyl-Trp-Ala-Trp-
983:10.1530/eje.0.1350407
614:for the treatment of
2073:Pralmorelin (GHRP-2)
1616:Eftansomatropin alfa
2115:Ibutamoren (MK-677)
1943:Modified GRF (1-29)
1843:Somatostatin (1-28)
1838:Somatostatin (GHIH)
1606:Bovine somatotropin
607:Examorelin reached
560:luteinizing hormone
497:amino acid sequence
473:centrally-penetrant
47:-Histidyl-2-methyl-
23:
2228:Experimental drugs
1207:Neuroendocrinology
709:10.1007/bf00191904
2210:
2209:
2192:
2165:
1989:
1909:
1883:Cyclosomatostatin
1747:
1723:Binding proteins:
1631:Lonapegsomatropin
1590:
1501:(11): 1299–1308.
1479:978-0-444-82933-7
1298:978-1-4398-1363-8
1219:10.1159/000126827
1137:(12): 4338–4341.
894:(11): 1599–1618.
778:978-94-011-4439-1
751:978-0-412-46630-4
570:(TSH) in humans.
506:
502:
451:), also known as
434:
433:
380:Interactive image
286:CompTox Dashboard
66:
62:
58:
54:
50:
46:
16:Chemical compound
2260:
2190:
2188:
2163:
1987:
1985:
1907:
1905:
1745:
1743:
1732:
1728:
1661:Somatropin pegol
1588:
1586:
1569:
1565:
1556:
1549:
1542:
1533:
1527:
1526:
1490:
1484:
1483:
1466:Ghigo E (1999).
1463:
1457:
1456:
1446:
1437:(5): 1644–1649.
1422:
1416:
1415:
1398:(4): 1090–1094.
1386:
1380:
1379:
1350:
1344:
1343:
1333:
1309:
1303:
1302:
1280:
1274:
1273:
1237:
1231:
1230:
1202:
1196:
1195:
1166:
1157:
1156:
1146:
1122:
1116:
1115:
1087:
1081:
1080:
1044:
1038:
1037:
1001:
995:
994:
965:
959:
958:
921:
912:
911:
883:
877:
876:
840:
829:
828:
803:(9): 1242–1259.
792:
783:
782:
762:
756:
755:
735:
729:
728:
692:
677:
676:
647:
587:ethinylestradiol
504:
500:
382:
362:
347:
341:
335:
329:
309:
308:
294:
292:
277:
257:
237:
217:
197:
187:
186:
172:
126:
64:
60:
56:
52:
48:
44:
31:
24:
22:
2268:
2267:
2263:
2262:
2261:
2259:
2258:
2257:
2213:
2212:
2211:
2206:
2189:
2180:
1986:
1977:
1906:
1897:
1744:
1735:
1730:
1611:Efpegsomatropin
1587:
1578:
1560:
1530:
1492:
1491:
1487:
1480:
1465:
1464:
1460:
1424:
1423:
1419:
1388:
1387:
1383:
1352:
1351:
1347:
1311:
1310:
1306:
1299:
1282:
1281:
1277:
1239:
1238:
1234:
1204:
1203:
1199:
1168:
1167:
1160:
1124:
1123:
1119:
1089:
1088:
1084:
1046:
1045:
1041:
1003:
1002:
998:
967:
966:
962:
923:
922:
915:
885:
884:
880:
842:
841:
832:
794:
793:
786:
779:
764:
763:
759:
752:
737:
736:
732:
694:
693:
680:
649:
648:
644:
640:
628:
612:clinical trials
510:
430:
427:
422:
417:
416:
405:
402:
397:
396:
385:
360:
350:
344:
338:
332:
312:
302:DTXSID401032408
288:
280:
260:
240:
220:
200:
183:
175:
155:
152:
147:
146:
124:
115:Pharmacokinetic
109:
74:
17:
12:
11:
5:
2266:
2264:
2256:
2255:
2250:
2245:
2240:
2235:
2230:
2225:
2215:
2214:
2208:
2207:
2205:
2204:
2196:
2194:
2182:
2181:
2179:
2178:
2173:
2168:
2159:
2154:
2145:
2144:
2139:
2127:
2122:
2117:
2112:
2107:
2102:
2097:
2085:
2080:
2075:
2070:
2065:
2060:
2055:
2050:
2045:
2040:
2035:
2030:
2025:
2020:
2015:
2010:
2008:Cortistatin-14
2005:
1993:
1991:
1979:
1978:
1976:
1975:
1966:
1965:
1960:
1955:
1950:
1945:
1940:
1935:
1930:
1925:
1913:
1911:
1908:(somatocrinin)
1899:
1898:
1896:
1895:
1890:
1885:
1880:
1871:
1870:
1865:
1860:
1855:
1850:
1845:
1840:
1835:
1830:
1825:
1820:
1815:
1810:
1805:
1800:
1795:
1790:
1785:
1780:
1775:
1770:
1768:Cortistatin-14
1765:
1760:
1751:
1749:
1746:(somatostatin)
1737:
1736:
1734:
1733:
1719:
1718:
1709:
1708:
1703:
1694:
1693:
1688:
1683:
1678:
1673:
1668:
1663:
1658:
1653:
1648:
1643:
1638:
1633:
1628:
1623:
1621:Growth hormone
1618:
1613:
1608:
1603:
1601:Albusomatropin
1594:
1592:
1589:(somatotropin)
1580:
1579:
1561:
1559:
1558:
1551:
1544:
1536:
1529:
1528:
1485:
1478:
1458:
1417:
1381:
1362:(2): 674–678.
1345:
1324:(3): 861–864.
1304:
1297:
1275:
1248:(5): 617–621.
1232:
1197:
1158:
1117:
1098:(1): 134–138.
1082:
1039:
1012:(5): 631–635.
996:
977:(4): 407–412.
960:
933:(6): 885–891.
913:
878:
851:(3): 303–310.
830:
784:
777:
757:
750:
730:
703:(5): 421–425.
678:
659:(3): 693–698.
641:
639:
636:
635:
634:
627:
624:
528:growth hormone
508:
432:
431:
429:
428:
425:
423:
420:
412:
411:
410:
407:
406:
404:
403:
400:
392:
391:
390:
387:
386:
384:
383:
375:
373:
365:
364:
358:
352:
351:
348:
342:
336:
330:
325:
319:
318:
314:
313:
311:
310:
297:
295:
282:
281:
279:
278:
270:
268:
262:
261:
259:
258:
250:
248:
242:
241:
239:
238:
230:
228:
222:
221:
219:
218:
210:
208:
202:
201:
199:
198:
190:
188:
177:
176:
174:
173:
165:
163:
157:
156:
154:
153:
150:
142:
141:
140:
137:
136:
132:
131:
128:
119:
118:
111:
110:
108:
107:
103:
101:
95:
94:
77:
75:administration
69:
68:
63:-phenylalanyl-
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
2265:
2254:
2251:
2249:
2246:
2244:
2241:
2239:
2236:
2234:
2231:
2229:
2226:
2224:
2221:
2220:
2218:
2202:
2198:
2197:
2195:
2193:
2191:(somatomedin)
2183:
2177:
2174:
2172:
2169:
2167:
2166:-Lys³)-GHRP-6
2160:
2158:
2157:Cortistatin-8
2155:
2153:
2150:
2147:
2146:
2143:
2140:
2138:
2135:
2131:
2128:
2126:
2123:
2121:
2118:
2116:
2113:
2111:
2108:
2106:
2103:
2101:
2098:
2096:
2093:
2089:
2086:
2084:
2081:
2079:
2076:
2074:
2071:
2069:
2066:
2064:
2061:
2059:
2056:
2054:
2051:
2049:
2046:
2044:
2041:
2039:
2036:
2034:
2031:
2029:
2026:
2024:
2021:
2019:
2016:
2014:
2011:
2009:
2006:
2004:
2001:
1998:
1995:
1994:
1992:
1990:
1980:
1974:
1971:
1968:
1967:
1964:
1961:
1959:
1956:
1954:
1951:
1949:
1946:
1944:
1941:
1939:
1936:
1934:
1931:
1929:
1926:
1924:
1921:
1918:
1915:
1914:
1912:
1910:
1900:
1894:
1891:
1889:
1886:
1884:
1881:
1879:
1876:
1873:
1872:
1869:
1866:
1864:
1861:
1859:
1856:
1854:
1851:
1849:
1846:
1844:
1841:
1839:
1836:
1834:
1831:
1829:
1826:
1824:
1823:Pentetreotide
1821:
1819:
1816:
1814:
1811:
1809:
1806:
1804:
1801:
1799:
1796:
1794:
1791:
1789:
1786:
1784:
1781:
1779:
1776:
1774:
1771:
1769:
1766:
1764:
1761:
1759:
1756:
1753:
1752:
1750:
1748:
1738:
1729:
1724:
1721:
1720:
1717:
1714:
1711:
1710:
1707:
1704:
1702:
1699:
1696:
1695:
1692:
1689:
1687:
1684:
1682:
1679:
1677:
1674:
1672:
1669:
1667:
1664:
1662:
1659:
1657:
1654:
1652:
1649:
1647:
1644:
1642:
1639:
1637:
1634:
1632:
1629:
1627:
1624:
1622:
1619:
1617:
1614:
1612:
1609:
1607:
1604:
1602:
1599:
1596:
1595:
1593:
1591:
1581:
1577:
1574:
1571:
1557:
1552:
1550:
1545:
1543:
1538:
1537:
1534:
1524:
1520:
1516:
1512:
1508:
1504:
1500:
1496:
1489:
1486:
1481:
1475:
1471:
1470:
1462:
1459:
1454:
1450:
1445:
1440:
1436:
1432:
1428:
1421:
1418:
1413:
1409:
1405:
1401:
1397:
1393:
1385:
1382:
1377:
1373:
1369:
1365:
1361:
1357:
1349:
1346:
1341:
1337:
1332:
1327:
1323:
1319:
1315:
1308:
1305:
1300:
1294:
1290:
1286:
1279:
1276:
1271:
1267:
1263:
1259:
1255:
1251:
1247:
1243:
1236:
1233:
1228:
1224:
1220:
1216:
1212:
1208:
1201:
1198:
1193:
1189:
1185:
1181:
1177:
1173:
1165:
1163:
1159:
1154:
1150:
1145:
1140:
1136:
1132:
1128:
1121:
1118:
1113:
1109:
1105:
1101:
1097:
1093:
1086:
1083:
1078:
1074:
1070:
1066:
1062:
1058:
1054:
1050:
1043:
1040:
1035:
1031:
1027:
1023:
1019:
1015:
1011:
1007:
1000:
997:
992:
988:
984:
980:
976:
972:
964:
961:
956:
952:
948:
944:
940:
936:
932:
928:
920:
918:
914:
909:
905:
901:
897:
893:
889:
882:
879:
874:
870:
866:
862:
858:
854:
850:
846:
839:
837:
835:
831:
826:
822:
818:
814:
810:
806:
802:
798:
791:
789:
785:
780:
774:
770:
769:
761:
758:
753:
747:
743:
742:
734:
731:
726:
722:
718:
714:
710:
706:
702:
698:
691:
689:
687:
685:
683:
679:
674:
670:
666:
662:
658:
654:
646:
643:
637:
633:
630:
629:
625:
623:
621:
617:
613:
610:
605:
602:
600:
596:
592:
589:, though not
588:
584:
580:
576:
571:
569:
565:
561:
557:
553:
549:
545:
541:
537:
533:
529:
525:
520:
518:
514:
498:
494:
490:
486:
483:(GHSR) and a
482:
478:
474:
470:
469:orally-active
466:
462:
458:
454:
450:
446:
442:
438:
424:
419:
415:
408:
399:
395:
388:
381:
377:
376:
374:
371:
366:
359:
357:
353:
326:
324:
320:
315:
307:
303:
299:
298:
296:
287:
283:
276:
272:
271:
269:
267:
263:
256:
252:
251:
249:
247:
243:
236:
232:
231:
229:
227:
223:
216:
212:
211:
209:
207:
203:
196:
192:
191:
189:
182:
178:
171:
167:
166:
164:
162:
158:
149:
145:
138:
133:
129:
127:
120:
116:
112:
105:
104:
102:
100:
96:
93:
89:
85:
81:
78:
76:
70:
43:
39:
36:Clinical data
34:
30:
25:
2243:Hexapeptides
2149:Antagonists:
2148:
2133:
2105:Capromorelin
2092:Non-peptide:
2091:
2017:
2003:Alexamorelin
1999:
1996:
1970:Antagonists:
1969:
1919:
1916:
1875:Antagonists:
1874:
1868:Veldoreotide
1754:
1722:
1712:
1698:Antagonists:
1697:
1656:Somatotropin
1597:
1498:
1494:
1488:
1468:
1461:
1434:
1430:
1420:
1395:
1391:
1384:
1359:
1355:
1348:
1321:
1317:
1307:
1288:
1278:
1245:
1241:
1235:
1213:(1): 51–56.
1210:
1206:
1200:
1178:(1): 83–88.
1175:
1171:
1134:
1130:
1120:
1095:
1091:
1085:
1055:(1): 43–45.
1052:
1048:
1042:
1009:
1005:
999:
974:
970:
963:
930:
926:
891:
887:
881:
848:
844:
800:
796:
767:
760:
740:
733:
700:
696:
656:
652:
645:
606:
603:
579:Testosterone
572:
550:(IGF-1) and
542:(ACTH), and
521:
452:
448:
444:
436:
435:
275:ChEMBL108335
123:Elimination
84:subcutaneous
59:-tryptophyl-
51:-tryptophyl-
2125:Macimorelin
2083:Tabimorelin
2078:Relamorelin
2058:Lenomorelin
1963:Tesamorelin
1958:Somatorelin
1893:Satoreotide
1818:Pasireotide
1803:NNC 26-9100
1783:Ilatreotide
1778:Edotreotide
1716:Atesidorsen
1706:Pegvisomant
1681:Somavaratan
1671:Sometribove
1646:Somapacitan
1641:Somagrebove
797:ChemMedChem
595:sex steroid
591:oxandrolone
532:pralmorelin
507:-Phe-Lys-NH
493:hexapeptide
363: g·mol
170:140703-51-1
135:Identifiers
130:~55 minutes
80:Intravenous
67:-lysinamide
41:Other names
2217:Categories
2100:Anamorelin
2088:Ulimorelin
2063:Livoletide
2053:Ipamorelin
1953:Sermorelin
1948:Rismorelin
1888:CYN-154806
1863:Vapreotide
1813:Octreotide
1808:Octreotate
1798:Lanreotide
1773:Depreotide
1691:Somidobove
1686:Somavubove
1651:Somatosalm
1576:modulators
1172:Metabolism
1092:Metabolism
638:References
566:(FSH), or
526:levels of
519:receptor.
491:. It is a
437:Examorelin
368:3D model (
356:Molar mass
255:09QF37C617
226:ChemSpider
206:IUPHAR/BPS
161:CAS Number
144:IUPAC name
88:intranasal
21:Examorelin
2142:LY-444711
2137:LY-426410
2134:Unsorted:
2130:SM-130686
2120:L-692,585
2110:CP-464709
2095:Adenosine
2068:LY-444711
1997:Agonists:
1988:(ghrelin)
1933:Dumorelin
1923:ALRN-5281
1917:Agonists:
1878:BIM-23056
1833:Seglitide
1793:L-817,818
1788:L-803,087
1758:BIM-23052
1755:Agonists:
1701:G120K-hGH
1598:Agonists:
1573:signaling
536:prolactin
495:with the
461:synthetic
453:hexarelin
125:half-life
73:Routes of
2203:instead.
2152:A-778193
2013:EP-51216
2000:Peptide:
1973:MZ-5-156
1928:CJC-1295
1920:Peptide:
1666:Somatrem
1523:21632578
1515:17040192
1270:31571160
1034:30980163
955:25480336
927:Peptides
908:83645573
873:71177320
865:19243281
825:24945528
817:17520591
725:19573322
626:See also
609:phase II
597:levels,
544:cortisol
465:peptidic
445:EP-23905
99:ATC code
55:-alanyl-
2176:YIL-781
2171:JMV2959
2023:Ghrelin
1853:SRIF-28
1848:SRIF-14
1453:9589671
1412:7714074
1376:7852535
1340:9062497
1262:8548947
1227:7731498
1192:9005975
1153:8954038
1112:7854159
1077:6791525
1069:7584696
1026:8548949
991:8921821
947:9285939
717:7957536
673:8126144
599:puberty
556:glucose
517:ghrelin
479:of the
477:agonist
455:, is a
449:MF-6003
361:887.059
323:Formula
235:5293503
195:6918297
181:PubChem
2048:GHRP-6
2043:GHRP-5
2038:GHRP-4
2033:GHRP-3
2028:GHRP-1
1858:TT-232
1828:RC-160
1763:CH-275
1521:
1513:
1476:
1451:
1410:
1374:
1338:
1295:
1268:
1260:
1225:
1190:
1151:
1110:
1075:
1067:
1032:
1024:
989:
953:
945:
906:
871:
863:
823:
815:
775:
748:
723:
715:
671:
585:, and
562:(LH),
524:plasma
513:GHRP-6
457:potent
394:SMILES
266:ChEMBL
2187:IGF-1
1568:IGF-1
1519:S2CID
1266:S2CID
1073:S2CID
1030:S2CID
951:S2CID
904:S2CID
869:S2CID
821:S2CID
721:S2CID
414:InChI
370:JSmol
2201:here
2199:See
1938:GHRH
1904:GHRH
1742:GHIH
1727:GHBP
1570:axis
1511:PMID
1474:ISBN
1449:PMID
1408:PMID
1372:PMID
1336:PMID
1293:ISBN
1258:PMID
1223:PMID
1188:PMID
1149:PMID
1108:PMID
1065:PMID
1022:PMID
987:PMID
943:PMID
861:PMID
813:PMID
773:ISBN
746:ISBN
713:PMID
669:PMID
618:and
499:His-
246:UNII
215:1100
117:data
106:None
92:oral
1984:GHS
1503:doi
1439:doi
1400:doi
1364:doi
1326:doi
1250:doi
1215:doi
1180:doi
1139:doi
1100:doi
1057:doi
1014:doi
979:doi
975:135
935:doi
896:doi
853:doi
805:doi
705:doi
661:doi
441:INN
291:EPA
185:CID
2219::
2132:;
2090:;
1585:GH
1564:GH
1517:.
1509:.
1499:15
1497:.
1447:.
1435:83
1433:.
1429:.
1406:.
1396:80
1394:.
1370:.
1360:80
1358:.
1334:.
1322:82
1320:.
1316:.
1287:.
1264:.
1256:.
1246:43
1244:.
1221:.
1211:61
1209:.
1186:.
1176:46
1174:.
1161:^
1147:.
1135:81
1133:.
1129:.
1106:.
1096:44
1094:.
1071:.
1063:.
1051:.
1028:.
1020:.
1010:43
1008:.
985:.
973:.
949:.
941:.
931:18
929:.
916:^
902:.
892:12
890:.
867:.
859:.
849:18
847:.
833:^
819:.
811:.
799:.
787:^
719:.
711:.
701:46
699:.
681:^
667:.
657:78
655:.
581:,
558:,
538:,
471:,
467:,
463:,
459:,
447:,
343:12
337:58
331:47
90:,
86:,
82:,
2164:D
2162:(
1566:/
1555:e
1548:t
1541:v
1525:.
1505::
1482:.
1455:.
1441::
1414:.
1402::
1378:.
1366::
1342:.
1328::
1301:.
1272:.
1252::
1229:.
1217::
1194:.
1182::
1155:.
1141::
1114:.
1102::
1079:.
1059::
1053:8
1036:.
1016::
993:.
981::
957:.
937::
910:.
898::
875:.
855::
827:.
807::
801:2
781:.
754:.
727:.
707::
675:.
663::
509:2
505:D
501:D
439:(
372:)
349:6
346:O
340:N
334:H
328:C
293:)
289:(
65:L
61:D
57:L
53:L
49:D
45:L
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
